688238 Stock Overview
A biotechnology company, focuses on the development of gene therapy vectors in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Obio Technology (Shanghai) Corp., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.04 |
| 52 Week High | CN¥7.38 |
| 52 Week Low | CN¥3.86 |
| Beta | 0.54 |
| 1 Month Change | 6.55% |
| 3 Month Change | -19.10% |
| 1 Year Change | -19.10% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -61.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688238 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | 8.4% | 7.6% | 3.3% |
| 1Y | -19.1% | 7.6% | 19.0% |
Return vs Industry: 688238 underperformed the CN Life Sciences industry which returned 5.3% over the past year.
Return vs Market: 688238 underperformed the CN Market which returned 17.4% over the past year.
Price Volatility
| 688238 volatility | |
|---|---|
| 688238 Average Weekly Movement | 6.4% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 10.6% |
| 10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 688238 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688238's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 722 | Guodong Jia | www.obiosh.com |
Obio Technology (Shanghai) Corp., Ltd., a biotechnology company, focuses on the development of gene therapy vectors in China. The company provides gene function and gene therapy research, and other CRO services, such as drug target and drug efficacy research. It also offers CDMO services, such as process development and testing, IND-CMC pharmaceutical research, and clinical sample GMP production for the research and development of genetic drugs.
Obio Technology (Shanghai) Corp., Ltd. Fundamentals Summary
| 688238 fundamental statistics | |
|---|---|
| Market cap | CN¥3.27b |
| Earnings (TTM) | -CN¥246.61m |
| Revenue (TTM) | CN¥251.68m |
13.0x
P/S Ratio-13.3x
P/E RatioIs 688238 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688238 income statement (TTM) | |
|---|---|
| Revenue | CN¥251.68m |
| Cost of Revenue | CN¥316.36m |
| Gross Profit | -CN¥64.68m |
| Other Expenses | CN¥181.93m |
| Earnings | -CN¥246.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 18, 2025
| Earnings per share (EPS) | -0.38 |
| Gross Margin | -25.70% |
| Net Profit Margin | -97.98% |
| Debt/Equity Ratio | 11.5% |
How did 688238 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 15:53 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Obio Technology (Shanghai) Corp., Ltd. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hao Wu | Chasing Securities |
| Wanhua Wu | China International Capital Corporation Limited |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |